Get the Stockscreener App
0.5404
4.29%
-0.0242
Pre-market:
.61
0.0696
+12.88%
20 20 Biolabs Inc stock is traded at $0.5404, with a volume of 35,834.
It is down -4.29% in the last 24 hours and up +18.17% over the past month.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
See More
Previous Close:
$0.5646
Open:
$0.579
24h Volume:
35,834
Relative Volume:
0.07
Market Cap:
$6.90M
Revenue:
$1.85M
Net Income/Loss:
$-5.56M
P/E Ratio:
-0.7126
EPS:
-0.7583
Net Cash Flow:
-
1W Performance:
-11.63%
1M Performance:
+18.17%
6M Performance:
-80.70%
1Y Performance:
+0.00%
1-Day Range:
$0.5341
$0.6091
1-Week Range:
$0.5341
$0.6212
52-Week Range:
$0.4011
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Name
20 20 Biolabs Inc
Sector
Industry
Phone
(240) 453-6339
Address
9430 KEY WEST AVENUE, ROCKVILLE
Compare AIDX vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
0.5404 | 6.90M | 1.85M | -5.56M | 0 | -0.7583 |
ABT
Abbott Laboratories
|
103.36 | 178.85B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.19B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 103.57B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 62.46B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 50.01B | 6.30B | 1.07B | 1.09B | 1.8406 |
20 20 Biolabs Inc Stock (AIDX) Latest News
20/20 Biolabs Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
20/20 Biolabs outlines FDA engagement, Medicare reimbursement pathway and commercial gains - TradingView
20/20 BioLabs says its cancer blood test hit record quarterly revenue - Stock Titan
20/20 Biolabs (AIDX) Holds Above $0.60 Support After Modest GainDefined Outcome ETF - dars.gov.et
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity - Barchart.com
20/20 BioLabs to Discuss Record Q2 OneTest Revenue, Next Generation Dx Summit Takeaways and Commercial Strategy at September 2 Webinar - Quiver Quantitative
20/20 BioLabs reschedules investor webinar to 2 pm ET on Sept 2 - scanx.trade
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity - Yahoo Finance
AIDX | 20/20 Biolabs, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
20/20 Biolabs, Inc. Common Stock (NASDAQ: AIDX) Stock Price, News & Analysis - kalkine.ca
Form 8K 20/20 BIOLABS For: 19 August By Investing.com - Investing.com Nigeria
20/20 Biolabs adjourns vote on charter amendment, elects directors at annual meeting - Investing.com
20/20 (AIDX) Update: Records a 1.45% Decrease to $0.51 at the Close; Price Context: the Near-Term Reference Band Stretches From $0.48 to $0.54 at the CloseMcClellan Oscillator - vinanet.vn
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level - Sahm
20/20 Biolabs Releases Q2 2026 Financial Results - AlphaStreet
20/20 Biolabs Q2 Results: EPS misses, revenue up 36% - scanx.trade
20/20 Biolabs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
20/20 Biolabs to host investor webinar; reports best quarterly cancer-test revenue to date - tradingview.com
After Taipei, Tokyo and Seoul, 20/20 BioLabs to discuss deal options - Stock Titan
20/20 BioLabs sets Aug 5 webinar on East Asia roll-up strategy - scanx.trade
20/20 BioLabs seeks East Asia M&A, JV deals to roll up AI blood test assets - scanx.trade
20/20 BioLabs meets potential partners in East Asia - Investing.com
20/20 BioLabs meets potential partners in East Asia By Investing.com - Investing.com Canada
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy - The Manila Times
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets - GlobeNewswire
20/20 Biolabs, Inc. Revenue Breakdown – NASDAQ:AIDX - TradingView
20/20 Biolabs Inc. (AIDX) Slides 4.1% as Stock Tests Key Support at $0.47Large Cap Trends - dars.gov.et
20/20 Biolabs, Inc. (AIDX) stock price, news, quote and history - Yahoo Finance UK
Rokit Healthcare, US 20/20 BioLabs to Co-Develop AI Multi-Cancer Prediction Platform - en.sedaily.com
20/20 BioLabs enters standstill pact on preferred stock - Investing.com
20/20 BioLabs Enters Temporary Standstill Agreement Limiting Series E Preferred Stock Conversions - Quiver Quantitative
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock - The Manila Times
Press Release: 20/20 BioLabs Announces Standstill Agreement With Streeterville Capital Regarding Series E Convertible Preferred Stock - Moomoo
20/20 Biolabs, Inc. Signs Standstill Agreement With Streeterville Capital – SEC 8-K Filing Details (July 2026) - Minichart
20/20 Biolabs Received Notice of Noncompliance - TradingView
20/20 Biolabs (Nasdaq: AIDX) signs standstill as Nasdaq flags bid-price issue - Stock Titan
Why Super Micro Computer Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
What Factors Led to 20/20 Biolabs' Dramatic Stock Collapse - Kavout | AI
20/20 BioLabs targets Medicare path as Q2 revenue jumps 30% - scanx.trade
20/20 BioLabs reports Q2 MCED revenue to be highest to date - Investing.com
20/20 BioLabs highlights OneTest™ strategy for Medicare coverage and reports strong Q2 revenue growth - Pluang
20/20 BioLabs Highlights Investor Webinar Focused on - GlobeNewswire
Virax Biolabs | 20-F: Registration statement / Annual report / Transition report - Moomoo
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
20/20 Biolabs (AIDX) Jumps Nearly 5% as Stock Approaches Key $0.67 ResistanceIchimoku Cloud - dars.gov.et
20/20 Biolabs to present OneTest webinar outlining Medicare pathway, modeling and reimbursement plan - TradingView
OneTest growth vision: 20/20 Biolabs (AIDX) targets Medicare MCED market - Stock Titan
20/20 BioLabs’ Multi-Cancer Early Detection Test Now Available to Evexia Diagnostics' 40,000+ U.S. Practitioners - The National Law Review
20/20 Biolabs Inc. (AIDX) Edges Higher in Low-Price Territory as Support HoldsWyckoff Spring - dars.gov.et
20/20 Biolabs, Inc. Actuals & Estimates (NASDAQ:AIDX) - TradingView
Price to sales forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20 20 Biolabs Inc Stock (AIDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.29%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):